Additional file 2: Figure S1. of Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients

Characterization of the patients’ bone mesenchymal stromal cells (MSCs). (DOCX 781 kb

Additional file 1: Table S1. of Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients

Method of kidney ultrasound imaging. DTPA kidney scan method. Cell parameters for the study patients. Table S2. Safety assessment of the mesenchymal stromal cell (MSC) infusion in 1 year following baseline visit of study patients. Table S3. Laboratory parameters at baseline, 1, 3, 6, 9, and 12 months of follow-up. Table S4. Changes in renal function parameters and blood pressure (BP) 1 year before, and at 1, 3, 6, 9, and 12 months after mesenchymal stromal cell (MSC) infusion. (DOCX 70 kb